Exam 2 Flashcards

1
Q

Anticholinergics- medications

A

atropine
ipratropium
scopolamine
glycopyrrolate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Anticholinergics- MOA

A

inhibits action of acetylcholine and neurotransmitters to decrease secretions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

aniticholinergic SE

A

constipation, dry eye, dry mucous membranes, blurry vision, tachycardia, GI obstruction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

anticholinergic- Considerations

A

monitor I and O (urinary retension, constipation)
antacids decrease absorption of these meds
VS (hypotension and tachycardia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Anticholinergics- teaching

A

teach about oral care
may cause drowsiness
do not admin with a fever

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Leukotriene Receptor Antagonists- meds

A

montelukast
zafirlukast

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

LTRA- MOA

A

stops the effects of leukotrienes in the body (narrowing of airways, and smooth muscle constriction)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

LTRA SE

A

SJS, increased liver enzymes, depression/suicidal thoughts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

LTRA- considerations

A

monitor ALT and AST
assess lung sounds, respiratory status
assess mood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

LTRA- teaching

A

its long acting, do not take during flare
take daily at night or 2 hours prior to exercise
educate to report any feelings of depression or suicidal thoughts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

mast cell stabilizers- med

A

cromolyn

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

mast cell stabalizers- MOA

A

decreases release of histamine, good for preventing exercise induced asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

mast cell stabilizers- SE

A

nasal, throat, or trachea irritation
wheezing
nausea
unpleasant taste
cough

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

mast cell stabilizers- considerations

A

assess lung sounds and respirator function
intranasal- assess for symptoms of rhinitis and rhinorrhea
reduction of other asthma med may be possible after 2-4 wks of therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

mast cell stabilizers-teaching

A

instruct on correct use of med (use routinely, don’t double dose, don’t discontinue without consulting HCP)
administer 10-15min prior to exposure of known allergy and no earlier than 60 min in advance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Inhaled corticosteroids- meds

A

beclomethasone dipropionate
budesonide
ciclesonide
flunisolide
fluticasone
momestasone
triameinolone acetonide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

inhaled corticosteroids- MOA

A

locally acting/suppressing inflammation and enhancing beta agonist response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

inhaled corticosteroids- SE

A

oral thrush/dry mouth
coughing
infections
pharyngeal irritation
chest pain/ dizziness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

inhaled corticosteroids- considerations

A

no systemic effects when inhaled
use bronchodilator before inhaled corticosteroid, all 5 min before admin of corticosteroids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

inhaled corticosteroids- teaching

A

rinse mouth after use

21
Q

LABA- meds

A

salmeterol, formoterol

22
Q

LABA- MOA

A

bronchodilation

23
Q

LABA- SE

A

headache
cough
tachycardia
HTN
paradoxical
bronchospasm
nervousness

24
Q

LABA- considerations

A

assess lung sounds, pulse, BP
use with MAOI and TCA may potentiate effects

25
Q

LABA- teaching

A

instruct patient using powder for inhalation never to exhale into diskus device and always to hold device in a level horizontal position. mouthpiece should be kept dry, never wash
Use in combination with ICS

26
Q

monoclonal antibody- meds

A

omalizumab

27
Q

monoclonal antibody- MOA

A

blocks inflammatory response

28
Q

monoclonal antibody SE

A

MI, DVT, infection site reaction

29
Q

monoclonal antibody- considerations

A

assess lung sounds and respiratory rate
assess for allergic reaction or s/s of MI and DVT

30
Q

monoclonal antibody- teaching

A

don’t decrease or discontinue other asthma meds, especially inhaled corticosteroids
call HCP for s/s or allergic reaction

31
Q

short-acting beta2 agonist- med

A

albuterol
levalbuterol

32
Q

short acting- MOA

A

relaxation of airway of smooth muscle with subsequent bronchodilation

33
Q

short-acting- SE

A

hyperactivity
hyperglycemia
hypokalemia
tremor
headache
nervousness
paradoxical bronchospasm

34
Q

short-acting- considerations

A

assess lung sounds
monitor pt for adverse effect
observe for paradoxical bronchospasm

35
Q

short-acting- teaching

A

educate on proper technique
advise to use 1st if concurrent use with other inhaler medications
notify HCP if breathing not improved or worsens

36
Q

benzodiazepines- meds

A

diazepam, midazolam, alprazolam

37
Q

hydantoi derivatives- meds

A

phenytoin, fosphenytoin

38
Q

barbiturates- meds

A

phenobarbital

39
Q

iminostilbenes- meds

A

carbamazepine, oxcarbazepine

40
Q

suicidal thoughts and behavior

A

all

41
Q

dizziness and drowsiness

A

all

42
Q

reduce other medication efficacy

A

benzodiazepines, hydantoin derivatives, iminostilbenes

43
Q

gingival hyperplasia and increased body hair

A

hydantoin derivatives

44
Q

vision loss

A

vigabatrin

45
Q

weight loss, impaired cognition and language difficulties

A

topiramate

46
Q

weight gain, insulin resistance and metabolic syndrome

A

iminostilbenes, valproic acid, gabapentin

47
Q

SIADH

A

iminostilbenes

48
Q

rescue med

A

benzodiazepines

49
Q

CBC and liver function testing regularly

A

all